• We recommend therapy-naïve individuals start combination ART containing tenofovir and emtricitabine as the preferred NRTI backbone .
  • We suggest abacavir and lamivudine is an acceptable alternative NRTI backbone in therapy-naïve individuals. In those with a baseline viral load >100,000, it should be used with caution if there are clinical reasons to prefer over tenofovir and emtricitabine.
  • The caution regarding baseline viral load does not apply if abacavir/lamivudine is used with dolutegravir.

Abacavir must not be used in individuals who are HLA-B*57:01-positive